Efficacy and Safety of Dalpiciclib Plus Toremifene in the Treatment of Advanced First-line HR Positive and HER2 Negative Breast Cancer: a Multicenter, Single Arm, Exploratory Phase II Clinical Study

NCT06495515 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

36

Enrollment

OTHER

Sponsor class

Conditions

CANCER
BRAEST CANCER
Late Frontline

Interventions

DRUG: Dalpiciclib，Toremifen

Sponsor

Tianjin Medical University Cancer Institute and Hospital